Tirzepatide
Mounjaro · Zepbound
Semaglutide's bigger, stronger cousin. Dual-action weight loss that's breaking clinical records.
Educational content only. Not medical advice. This compound may be regulated in your jurisdiction. Consult a healthcare professional.
01 What is Tirzepatide?
If Semaglutide was the revolution, Tirzepatide is the evolution. Made by Eli Lilly (vs Novo Nordisk's Semaglutide), it targets TWO receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action appears to produce even greater weight loss than Semaglutide alone. The SURMOUNT trial results were staggering: patients lost an average of 22.5% of their body weight on the highest dose. That's nearly a quarter of total body weight — results that were previously only achievable with bariatric surgery.
02 How Does It Work?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1 suppresses appetite and slows gastric emptying (same as Semaglutide). GIP adds additional insulin secretion stimulation, improved fat metabolism, and may have direct effects on adipose tissue. The dual action creates a synergistic effect — the two hormones working together produce greater metabolic improvements than either alone.
03 What Does The Research Say?
Strong clinical evidence from human trials.
SURMOUNT-1: 22.5% body weight loss at highest dose (15mg) over 72 weeks. SURMOUNT-2 (diabetes patients): 14.7% weight loss. SURMOUNT-3 (with lifestyle intervention): 26.6% weight loss. These are the highest weight loss numbers ever seen in a pharmaceutical trial. Also approved for Type 2 diabetes (Mounjaro). Cardiovascular outcome trials are ongoing.
04 Reported Dosages
Research literature dosages only. NOT medical recommendations. Always consult a healthcare professional.
Prescription only. Must be prescribed and supervised by a doctor. Mounjaro/Zepbound: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly injection, escalated over 20 weeks. Do NOT use without medical supervision.
05 Side Effects & Risks
Similar to Semaglutide: nausea, vomiting, diarrhea, constipation (especially during dose escalation). Potential for pancreatitis, gallbladder issues. Thyroid tumour risk (rodent studies). Muscle loss is a concern — strength training strongly recommended.
06 Legal Status
Prescription only. Mounjaro approved for diabetes. Zepbound for weight management (pending).
Prescription only. FDA-approved (Mounjaro for diabetes, Zepbound for weight loss).
Prescription only. EMA-approved for diabetes.
Prescription only. TGA-approved for diabetes.
Goal Guides for Tirzepatide
Explore how Tirzepatide may support specific health goals: